article thumbnail

Knowde Group Inc.™ Enters Into a Strategic Partnership with LMC Manna Research to Drive Quality and Collaboration in the Conduct of Cannabis and Psychedelic Clinical Trials.

Cannabis Law Report

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Collectively, between the two organizations we offer a full-service package from protocol development to timely and successful clinical trial execution.”.

article thumbnail

Flora Growth Forms Flora Pharma Division, Launches Global Clinical Trials

Cannabis Law Report

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Article: Intellectual Property Due Diligence in Psychedelics

Cannabis Law Report

For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art. However, that does not mean that the path to patents is closed off. Originally Published At Microdose.

article thumbnail

Oxford Cannabinoid Technologies Holdings plc: Post IPO Review & Notice of Pre-Close Trading Update

Cannabis Law Report

This includes First Time in Human (“FTiH”) clinical trials, which are expected to commence in 2022, for the Group’s lead compound OCT461201, a selective cannabinoid receptor type 2 (“CB2”) agonist with initial indications in the areas of post herpetic neuralgia and visceral pain caused by irritable bowel syndrome.

article thumbnail

MAPS – Position: European Regulatory Lead

Cannabis Law Report

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. The right candidate will have a passion for clinical research in novel therapeutics and a proven track record of regulatory affairs experience. Key Responsibilities.

article thumbnail

Position: European Regulatory Lead – Remote MAPS PBC California Remote

Cannabis Law Report

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. Competitive benefit package includes : Paid Time Off (PTO). European Regulatory Lead Executive Summary. Key Responsibilities.

article thumbnail

Press Release: Numinus Wellness research facility licensed by Health Canada to supply psilocybin mushrooms

Cannabis Law Report

Numinus Bioscience said that it is prepared to supply psilocybin in whole mushroom form, through three packaged doses equivalent to 10, 15, and 25mg of psilocybin. This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. Numinus Wellness Inc.